Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Net Income (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Net Income for 4 consecutive years, with -$21.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Income rose 71.62% to -$21.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$221.1 million, a 33.88% increase, with the full-year FY2025 number at -$221.1 million, up 33.88% from a year prior.
  • Net Income was -$21.1 million for Q4 2025 at Phathom Pharmaceuticals, up from -$30.0 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$21.1 million in Q4 2025 to a low of -$94.3 million in Q1 2025.
  • A 4-year average of -$59.6 million and a median of -$53.0 million in 2022 define the central range for Net Income.
  • Peak YoY movement for Net Income: tumbled 123.2% in 2024, then surged 71.62% in 2025.
  • Phathom Pharmaceuticals' Net Income stood at -$55.0 million in 2022, then plummeted by 44.76% to -$79.6 million in 2023, then increased by 6.36% to -$74.5 million in 2024, then soared by 71.62% to -$21.1 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Net Income are -$21.1 million (Q4 2025), -$30.0 million (Q3 2025), and -$75.7 million (Q2 2025).